Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 2 Stomach Neoplasms 1 Sarcoma 1 Prostatic Neoplasms 1 Osteosarcoma 1 Neoplasm Metastasis 1 Lymphatic Metastasis 1 Ependymoma 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma, Renal Cell 1 Adenocarcinoma 1

Interventions

Doxorubicin 62 Ifosfamide 39 Gemcitabine 29 Radiotherapy 27 Filgrastim 27 Cyclophosphamide 26 Docetaxel 19 Vincristine 18 pembrolizumab 17 Etoposide 17 pazopanib 16 Cisplatin 16 Nivolumab 15 Trabectedin 14 apatinib 13 Magnetic Resonance Spectroscopy 13 Carboplatin 12 Irinotecan 11 Bevacizumab 11 anlotinib 10 Temozolomide 10 Surgical Procedures, Operative 10 Sirolimus 10 camrelizumab 9 Sorafenib 9 Paclitaxel 9 Ipilimumab 9 Injections 9 Dactinomycin 9 Topotecan 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Sarcoma × Metastasectomy × Clear all

NCT06815666 2026-03-04

BAL Fluid Biomarkers in Sarcoma

University Health Network, Toronto

Phase 2 Recruiting

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡